Evidence map›Paper›PMID 41562250›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Targeting WTAP/ROR1/WNT5A-Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy.

Xiaoyong Chen, Bo Pang, Yun Liu, Jiangwei Wang, Lanhui Zheng, Yuzhou Chang, Yingxuan Sun, Haoyuan Sun, Huiyuan Chen, Jiawei Cai and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiaoyong ChenDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Bo PangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yun LiuDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jiangwei WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Lanhui ZhengDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuzhou ChangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yingxuan SunBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Haoyuan SunBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Huiyuan ChenBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Jiawei CaiDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Zanyi WuDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Qing ChangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Yongzhi WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Dezhi KangDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Tao JiangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ruichao ChaiBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0003-3451-8871

Funding

Beijing Key Laboratory of Drug Innovation for Neuro-Oncology Z241100009024044Beijing Municipal Health Commission JYY2023-2Beijing Postdoctoral Research FundingChina Postdoctoral Science Foundation 2024M762188China Postdoctoral Science Foundation 2025T180557Fundings from Beijing Neurosurgical Institute 11000025T000003319495High-level Talents Research Start-up Project of the First Affiliated Hospital, Fujian Medical University YJRC4194National Natural Science Foundation of China 82272867National Natural Science Foundation of China 82403757NSFC/RGC Collaborative Research Scheme 82261160578The Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0525300
6 · The paper itself

Abstract

Glioma stem cells (GSCs) can trans-differentiate into glioma-derived endothelial cells (GDECs), contributing to glioblastoma progression and therapy resistance. The molecular basis underpinning GSC-GDEC differentiation remain incompletely elucidated. Here, ROR1 is identified as a key regulator of GSC-to-GDEC differentiation under hypoxia. ROR1 expression is elevated in GDECs across patient-derived cells, xenografts, and tumor samples, confirmed by single-cell multiomics, Western blotting, and multiplex staining. Mechanistically, WNT5A, secreted by tumor-associated macrophages (TAMs) under hypoxia, activates ROR1-mediated Wingless-type MMTV integration site family (WNT) signaling in GSCs, promoting GDEC formation. Interestingly, hypoxia-induced WTAP not only enhances ROR1 stability through m

Indexed as

Brain NeoplasmsGliomaMacrophagesNeoplastic Stem CellsNeovascularization, PathologicReceptor Tyrosine Kinase-like Orphan ReceptorsRNA Splicing FactorsWnt-5a ProteinAnimalsEndothelial CellsGlioblastomaHumansMiceReceptor Tyrosine Kinase-like Orphan ReceptorsRNA Splicing FactorsROR1 protein, humanWnt-5a ProteinWNT5A protein, humanendothelial differentiationglioma stem cellm6Amacrophagetargeted therapy

Identifiers

PMID41562250
PMCPMC13073320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.